Beautiful Virgin Islands

Tuesday, Jul 01, 2025

China Mulls Mixing Different COVID-19 Vaccines To Improve Efficacy Of Jabs

China Mulls Mixing Different COVID-19 Vaccines To Improve Efficacy Of Jabs

Authorities have to "consider ways to solve the issue that efficacy rates of existing vaccines are not high", Chinese media outlet The Paper reported.
China is considering the mixing of different Covid-19 vaccines to improve the relatively low efficacy of its existing options, a top health expert has told a conference.

Authorities have to "consider ways to solve the issue that efficacy rates of existing vaccines are not high", Chinese media outlet The Paper reported, citing Gao Fu, the head of the Center for Disease Control and Prevention.

His comments mark the first time a top Chinese expert has publicly alluded to the relatively low efficacy of the country's vaccines, as China forges ahead in its mass vaccination campaign and exports its jabs around the world.

China has administered around 161 million doses since vaccinations began last year -- most people will require two shots -- and aims to fully inoculate 40 percent of its 1.4 billion population by June.

But many have been slow to sign up for jabs, with life largely back to normal within China's borders and domestic outbreaks under control.

Gao has previously stressed the best way to prevent the spread of Covid-19 is vaccination, and said in a recent state media interview that China aims to vaccinate 70 percent to 80 percent of its population between the end of this year and mid-2022.

At the conference in Chengdu on Saturday, Gao added that an option to overcome the efficacy problem is to alternate the use of vaccine doses that tap different technologies.

This is an option that health experts outside China are studying as well.

Gao said experts should not ignore mRNA vaccines just because there are already several coronavirus jabs in the country, urging for further development, The Paper reported.

Currently, none of China's jabs conditionally approved for the market are mRNA vaccines, but products that use the technology include those by US pharma giant Pfizer and German start-up BioNTech, as well as by Moderna.

China has four conditionally approved vaccines, whose published efficacy rates remain behind rival jabs by Pfizer-BioNTech and Moderna, which have 95 percent and 94 percent rates respectively.

China's Sinovac previously said trials in Brazil showed around 50 percent efficacy in preventing infection and 80 percent efficacy in preventing cases requiring medical intervention.

Sinopharm's vaccines have efficacy rates of 79.34 percent and 72.51 percent respectively, while the overall efficacy for CanSino's stands at 65.28 percent after 28 days.
Newsletter

Related Articles

Beautiful Virgin Islands
0:00
0:00
Close
Robots Compete in Football Tournament in China Amid Injuries
Trump Administration Considers Withdrawal of Funding for Hospitals Providing Gender Treatment to Minors
Texas Enacts Law Allowing Gold and Silver Transactions
China Unveils Miniature Insect-Like Surveillance Drone
OpenAI Secures Multimillion-Dollar AI Contracts with Pentagon, India, and Grab
Marc Marquez Claims Victory at Dutch Grand Prix Amidst Family Misfortune
Germany Votes to Suspend Family Reunification for Asylum Seekers
Elon Musk Critiques Senate Budget Proposal Over Job Losses and Strategic Risks
Los Angeles Riots ended with Federal Investigations into Funding
Budapest Pride Parade Draws 200,000 Participants Amid Government Ban
Southern Europe Experiences Extreme Heat
Xiaomi's YU7 SUV Launch Garners Record Pre-Orders Amid Market Challenges
Jeff Bezos and Lauren Sanchez's Lavish Wedding in Venice
Russia Launches Largest Air Assault on Ukraine Since Invasion
Education Secretary Announces Overhaul of Complaints System Amid Rising Parental Grievances
Massive Anti-Government Protests Erupt in Belgrade
Trump Ends Trade Talks with Canada Over Digital Services Tax
UK Government Softens Welfare Reform Plans Amid Labour Party Rebellion
Labour Faces Rebellion Over Disability Benefit Reforms Ahead of Key Vote
Jeff Bezos and Lauren Sánchez Host Lavish Wedding in Venice Amid Protests
Trump Asserts Readiness for Further Strikes on Iran Amid Nuclear Tensions
North Korea to Open New Beach Resort to Boost Tourism Economy
UK Labour Party Faces Internal Tensions Over Welfare Reforms
Andrew Cuomo Hints at Potential November Comeback Amid Democratic Primary Results
Curtis Sliwa Champions His Vision for New York City Amid Rising Crime Concerns
Federal Reserve Proposes Changes to Capital Rule Affecting Major Banks
EU TO HUNGARY: LET THEM PRIDE OR PREP FOR SHADE. ORBÁN TO EU: STAY IN YOUR LANE AND FIX YOUR OWN MESS.
Trump Escalates Criticism of Media Over Iran Strike Coverage
Trump Announces Upcoming US-Iran Meeting Amid Controversial Airstrikes
Trump Moves to Reshape Middle East Following Israel-Iran Conflict
Big Four Accounting Firms Fined in Exam Cheating Scandal
NATO Members Agree to 5% Defense Spending Target by 2035
Australia's Star Casino Secures $195 Million Rescue Package Amid Challenges
UK to Enhance Nuclear Capabilities with Acquisition of F-35A Fighter Jets
Russian Shadow Payments via Cryptocurrency Reach $9 Billion
Explosions Rock Doha as Iranian Missiles Target Qatar
“You Have 12 Hours to Flee”: Israeli Threat Campaign Targets Surviving Iranian Officials
Macron and Merz: Europe must arm itself in an unstable world
Germany and Italy Under Pressure to Repatriate $245bn of Gold from US Vaults
Airlines Evaluate Flight Cancellations Amid Escalating US-Iran Tensions
Starmer Invites Innovators to Join Government Talent Scheme
UK Economy’s Strong Opening Quarter Shows Signs of Cooling
Harrods Seeks Court Order to Secure Al Fayed Estate for Victims
BA and Singapore Airlines Cancel Dubai Flights Amid Middle East Tensions
Trump Faces Backlash from MAGA Base Over Iran Strikes
Meta Bets $14 B on Alexandr Wang to Drive AI Ambitions
WATCH: Israeli forces show the aftermath of a massive airstrike at Iran's Isfahan nuclear site
FedEx Founder Fred Smith, ‘Heart and Soul’ of the Company, Dies at 80
Chinese Factories Shift Away from U.S. Amid Trump‑Era Tariffs
Pimco Seizes Opportunity in Japan’s Dislocated Bond Market
×